


FORM PTO-1449



PATENTS AND OTHER ITEMS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

ATTY. DCK. NO.
225/273SERIAL NO.
08/872,527APPLICANT:
Dr. Yajun GuoFILING DATE:
6/11/97GROUP:
1644

U.S. PATENT DOCUMENTS

GROUP 1644

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
TC	AA	4,844,893	7/4/89	Honsik, et al.	-	-	
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TC	AQ		Shi, <i>et al.</i> "Adoptive Immunotherapy for Hepatocellular Carcinoma with Tumor Specific CTLs Generated <i>In Vitro</i> by Stimulating TILs or PBLs with the Cytokine Treated Tumor Cells and a Bispecific Monoclonal Antibody" <u>Proc. Am. Assoc. Cancer Res.</u> 37: 480, Abstract No. 3278 (1996)
TC	AR	✓	Guo, <i>et al.</i> "Effective Tumor Vaccines Generated by <i>In Vitro</i> Modification of Tumor Cells With Cytokines and Bispecific Monoclonal Antibodies" <u>Nature Medicine</u> 3(4): 451-455 (1997)
TC	AS	✓	Azuma, <i>et al.</i> "Induction of Intracellular Adhesion Molecule 1 on Small Cell Carcinoma Cell Lines by Gamma-Interferon Enhances Spontaneous and Bispecific Anti-CD3 X Antitumor Antibody-directed Lymphokine-activated Killer Cell Cytotoxicity" <u>Cancer Research</u> 52: 4890-4894 (1992)
TC	AT	✓	Demanet, <i>et al.</i> "Bispecific Antibody-mediated Immunotherapy of the BCL1 Lymphoma: Increased Efficacy with Multiple Injections and CD28-Induced Costimulation" <u>Blood</u> 87(10): 4390-4398 (1996)
TC	AU	✓	Hombach, <i>et al.</i> "Specific Activation of Resting T Cells Against Tumour Cells by Bispecific Antibodies and CD28-Mediated Costimulation is Accompanied by Th1 Differentiation and Recruitment of MHC-independent Cytotoxicity" <u>Clinical and Experimental Immunology</u> 108: 352-357 (1997)
	AV		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
TC	AX		Guo, <i>et al.</i> "Effective Tumor Vaccine Generated by Fusion of Hepatoma Cells with Activated B Cells" <u>Science</u> 263:518-520 (1994)
	AY		Leach, <i>et al.</i> "Enhancement of Antitumor Immunity by CTLA-4 Blockade" <u>Science</u> 271:1734-1736 (1996)
	AZ		Takahashi, <i>et al.</i> "Inhibition of Human Colon Cancer Growth by Antibody-Directed Human LAK Cells in SCID Mice" <u>Science</u> 259:1460-1463 (1993)
	BA		Luboldt, <i>et al.</i> "Selective Loss of Human Leukocyte Antigen Class I Allele Expression in Advanced Renal Cell Carcinoma" <u>Cancer Research</u> 56:826-830 (1996)
	BB		Nitta, <i>et al.</i> "Induction of cytotoxicity in human T cells coated with anti-glioma x anti-CD3 bispecific antibody against human glioma cells" <u>J. Neurosurg.</u> 72:476-481 (1990)
	BC	✓	Renner, <i>et al.</i> "Cure of Xenografted Human Tumors by Biospecific Monoclonal Antibodies and Human T Cells" <u>Science</u> 264:833-835 (1994)
	BD	✓	Bohlen, <i>et al.</i> "Lysis of Malignant B Cells From Patients With B-Chronic Lymphocytic Leukemia by Autologous T Cells Activated with CD3 x CD19 Bispecific Antibodies in Combination With Bivalent CD28 Antibodies" <u>Blood</u> 82(6):1803-1812 (1993)
	BE		Shen, <i>et al.</i> "Cloned Dendritic Cells Can Present Exogenous Antigens on Both MHC Class I and Class II Molecules" <u>J. Immunol.</u> 158:2723-2730 (1997)
	BF		Cayeux, <i>et al.</i> "Influence of Gene-Modified (IL-7, IL-4, and B7) Tumor Cell Vaccines on Tumor Antigen Presentation" <u>J. Immunol.</u> 158:2834-2841 (1997)
	BG		Keane-Myers, <i>et al.</i> "B7-CD28/CTLA-4 Costimulatory Pathways Are Required for the Development of T Helper Cell 2-Mediated Allergic Airway Responses to Inhaled Antigens" <u>J. Immunol.</u> 158:2042-2049 (1997)
	BH		Hunter, <i>et al.</i> "The Role of the CD28/B7 Interaction in the Regulation of NK Cell Responses During Infection with <i>Toxoplasma gondii</i> " <u>J. Immunol.</u> 158:2285-2293 (1997)
	BI		Svensson, <i>et al.</i> "Bone Marrow-Derived Dendritic Cells Can Process Bacteria for MHC-I and MHC-II Presentation to T Cells" <u>J. Immunol.</u> 158:4229-4236 (1997)
	BJ		Lakkis, <i>et al.</i> "Blocking the CD28-B7 Cell Costimulation Pathway Induces Long Term Cardiac Allograft Acceptance in the Absence of IL-4" <u>J. Immunol.</u> 158:2443-2448 (1997)
	BK		Ranheim, <i>et al.</i> "Activated T Cells Induce Expression of B7/BB1 on Normal or Leukemic B Cells through a CD40-dependent Signal" <u>J. Exp. Med.</u> 177:925-935 (1993)
	BL		Azuma, <i>et al.</i> "B70 antigen is a second ligand for CTLA-4 and CD28" <u>Nature</u> 366:76-79 (1993)
	BM		Sethna, <i>et al.</i> "A Negative Regulatory Function of B7 Revealed in B7-1 Transgenic Mice" <u>Immunity</u> 1:415-421 (1994)
	BN		Green, <i>et al.</i> "Absence of B7-Dependent Responses in CD28-Deficient Mice" <u>Immunity</u> 1:501-508 (1994)
	BO		Townsend, <i>et al.</i> "Tumor Rejection After Direct Costimulation of CD8 ⁺ T Cells by B7-Transfected Melanoma Cells" <u>Science</u> 259:368-370 (1993)
	BP		Walunas, <i>et al.</i> "CTLA-4 Can Function as a Negative Regulator of T Cell Activation" <u>Immunity</u> 1:405-413 (1994)
TK	BQ		Grabbe, <i>et al.</i> "Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy" <u>Trends</u> 16(3):117-121 (1995)

LIST OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT:


Dr. Yajun Guo

FILING DATE:

June 11, 1997

GROUP:

Unassigned



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
	AL							
	AM							
	AN							
	AO							
	AP							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

TC	AQ		Bohlen, <i>et al.</i> "Prevention of Epstein-Barr Virus-induced Human B-Cell Lymphoma in Severe Combined Immunodeficient Mice Treated with CD3xCD19 Bispecific Antibodies, CD28 Monospecific Antibodies, and Autologous T Cells" <u>Cancer Research</u> 57:1704-1709 (1997)
TC	AR		Gaczynska, <i>et al.</i> "γ-Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes" <u>Nature</u> 365:264-266 (1993)
TC	AS		Gong, <i>et al.</i> "Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells" <u>Nature Medicine</u> 3(5):558-561 (1997)
TC	AT		Chen, <i>et al.</i> "Costimulation of Antitumor Immunity by the B7 Counterreceptor for the T Lymphocyte Molecules CD28 and CTLA-4" <u>Cell</u> 71:1093-1102 (1992)
TC	AU		Hsu, <i>et al.</i> "Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells" <u>Nature Medicine</u> 2(1):52-58 (1996)
TC	AV		Nitta, <i>et al.</i> "Bispecific F(ab') ₂ monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytotoxicity of human T cells" <u>Eur. J. Immunol.</u> 19:1437-1441 (1989)
TC	AW	✓	Chapoval, <i>et al.</i> "Anti-CD3 x Anti-Tumor F(ab') ₂ Bifunctional Antibody Activates and Retargets Tumor-Infiltrating Lymphocytes" <u>J. Immunol.</u> pp. 1296-1303 (1995)

FORM PTO-1449

ATTY. DOCKET NO.
225/273SERIAL NO.
08/872,527OFFICE OF PATENTS AND OTHER ITEMS FOR APPLICANT'S
INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICANT:
Dr. Yajun GuoFILING DATE:
June 11, 1997GROUP:
Unassigned

1644

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

NYC	BR		Yang, <i>et al.</i> "Antitumor Immunity Elicited by Tumor Cells Transfected with B7-2, a Second Ligand for CD28/CTLA-4 Costimulatory Molecules" <u>J. Immunol.</u> 154:2794-2800 (1995)
	BS	✓	Chen, <i>et al.</i> "Tumor Immunogenicity Determines the Effect of B7 Costimulation of T Cell-mediated Tumor Immunity" <u>J. Exp. Med.</u> 179:523-532 (1994)
	BT	✓	Li, <i>et al.</i> "Costimulation of Tumor-Reactive CD4 ⁺ and CD8 ⁺ T Lymphocytes by B7, a Natural Ligand for CD28, Can Be Used to Treat Established Mouse Melanoma" <u>J. Immunol.</u> 153:421 (1994)
	BU		Boussiotis, <i>et al.</i> "Blockade of the CD28 co-stimulatory pathway: a means to induce tolerance" <u>J. Immunol.</u> 6:797-807 (1994)
	BV		Ohnishi, <i>et al.</i> "CD28 Cross-Linking Augments TCR-Mediated Signals and Costimulates Superantigen Responses" <u>J. Immunol.</u> 154:3180-3193 (1995)
	BW		Darlington, <i>et al.</i> "Expression of Liver Phenotypes in Cultured Mouse Hepatoma Cells" <u>J. NCI</u> 64(4):809-815 (1980)
	BX		Linsley, "Distinct roles for CD28 and Cytotoxic T Lymphocyte-associated Molecule-4 Receptors during T Cell Activation?" <u>J. Exp. Med.</u> 182:289-292 (1995)
	BY		Yang, <i>et al.</i> "In Vitro Priming of Tumor-Reactive Cytolytic T Lymphocytes by Combining IL-10 with B7-CD28 Costimulation" <u>J. Immunol.</u> 155:3897-3903 (1995)
	BZ		Li, <i>et al.</i> "Costimulation by CD48 and B7-1 Induces Immunity against Poorly Immunogenic Tumors" <u>J. Exp. Med.</u> 183:639-644 (1996)
	CA		MacLean, <i>et al.</i> "Anti-CD3:Anti-IL-2 Receptor-Bispecific mAb-Mediated Immunomodulation" <u>J. Immunol.</u> 155:3674-3682 (1995)
	CB		Chen, <i>et al.</i> "Potent antitumor activity of a new class of tumour-specific killer cells" <u>Nature</u> 385:78-80 (1997)
	CC		Huang, <i>et al.</i> "Role of Bone Marrow-Derived Cells in Presenting MHC Class I-Restricted Tumor Antigens" <u>Science</u> 264:961-965 (1994)
	CD		Lanzavecchia, <i>et al.</i> "The use of hybrid hybridomas to target human cytotoxic T lymphocytes" <u>Eur. J. Immunol.</u> 17:105-111 (1987)
	CE		Krummel, <i>et al.</i> "CD28 and CTLA-4 Have Opposing Effects on the Response of T Cells to Stimulation" <u>J. Exp. Med.</u> 182:459-465 (1995)
	CF		Linsley, "Distinct roles for CD28 and Cytotoxic T Lymphocyte-associated Molecule-4 Receptors during T Cell Activation?" <u>J. Exp. Med.</u> 182:289-292 (1995)
	CG		Li, <i>et al.</i> "Costimulation by CD48 and B7-1 Induces Immunity against Poorly Immunogenic Tumors" <u>J. Exp. Med.</u> 183:639-644 (1996)
	CH		Cohen "Mounting a Targeted Strike on Unwanted Immune Responses" <u>Science</u> 257:751 (1992)
	CI		Grabbe, <i>et al.</i> "Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy?" <u>Trends</u> 16(3):117-121 (1995)
	CJ		Greenfield, <i>et al.</i> "B7.2 Expressed by T Cells Does Not Induce CD28-Mediated Costimulatory Activity but Retains CTLA4 Binding" <u>J. Immunol.</u> 158:2025-2034 (1997)
NYC	CK		Bluestone "Is CTLA-4 a Master Switch for Peripheral T Cell Tolerance?" <u>J. Immunol.</u> 158:1989-1993 (1997)